SGC707 |
Catalog No.GC12874
One-Click Copy Product Info
|
SGC707 is a selective allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) (IC50=31nM, Kd=53nM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1687736-54-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SGC707 is a selective allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) (IC50=31nM, Kd=53nM). SGC707 can be used in research related to cancers (such as glioblastoma, hepatocellular carcinoma), metabolic diseases (such as non-alcoholic fatty liver disease, atherosclerosis), and antiarrhythmic effects[1-4].
In vitro, SGC707 (10μM) was used to treat RS4;11 acute leukemia cells for 48 hours. SGC707 had no effect on cell growth and showed minimal downregulation of ADMA (asymmetric dimethylarginine) levels[5]. SGC707 (10μM) was used to treat glioblastoma cells (U251, U87, A172) for 48-96 hours. SGC707 impaired cell growth and abolished glycolysis in cancer cells[6].
In vivo, SGC707 (30mg/kg; once daily) was intraperitoneally injected into a mouse model of endometriosis for 5 consecutive days. SGC707 inhibited the occurrence of endometriosis, promoted deciduoma formation, and improved embryonic development[7]. SGC707 (10mg/kg; three times per week) was intraperitoneally injected into apoE knockout mice for 6 consecutive weeks. SGC707 alleviated hepatic steatosis, reduced weight gain, and altered white adipose tissue morphology[8].
References:
[1] Kaniskan HÜ, Szewczyk MM, Yu Z, et al. A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). Angew Chem Int Ed Engl. 2015 Apr 20;54(17):5166-70.
[2] de Jong LM, Zhang Z, den Hartog Y, et al. PRMT3 inhibitor SGC707 reduces triglyceride levels and induces pruritus in Western-type diet-fed LDL receptor knockout mice. Sci Rep. 2022 Jan 10;12(1):483.
[3] Wang Y, Wang C, Guan X, et al. PRMT3-Mediated Arginine Methylation of METTL14 Promotes Malignant Progression and Treatment Resistance in Endometrial Carcinoma. Adv Sci (Weinh). 2023 Dec;10(36):e2303812.
[4] Zhang X, Hao Y, Han D, et al. PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification. Circulation. 2026 Mar 9.
[5] Zou W, Li M, Wan S, et al. Discovery of PRMT3 Degrader for the Treatment of Acute Leukemia. Adv Sci (Weinh). 2024 Oct;11(38):e2405963.
[6] Liao Y, Luo Z, Lin Y, et al. PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism. Cell Death Dis. 2022 Nov 9;13(11):943.
[7] Sun F, Chen Y, Li Y, et al. PRMT3-mediated FOXO1 arginine methylation exacerbates oxidative stress-induced decidualization defects in the eutopic endometrium of endometriosis. Cell Mol Life Sci. 2025 Dec 27;83(1):45.
[8] Hoekstra M, Nahon JE, de Jong LM, et al. Inhibition of PRMT3 activity reduces hepatic steatosis without altering atherosclerosis susceptibility in apoE knockout mice. Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1402-1409.
| Cell experiment [1]: | |
Cell lines | Glioblastoma cell line (U251, U87 and A172) |
Preparation Method | The U251, U87 and A172 were cultured in DMEM medium with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. The cells were treated with SGC707 (10μM) for 48-96 hours. |
Reaction Conditions | 10μM; 48-96 hours |
Applications | Pharmacological inhibition of PRMT3 with SGC707 impaired the growth of GBM cells and abolished glycolysis. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice (six-week-old female and eight-week-old male) |
Preparation Method | A mouse model of endometriosis was established. One month after establishing the endometriosis model, the mice with endometriosis were divided into an experimental group and a control group, and a decidualization model was established. The experimental group mice were intraperitoneally injected with SGC707 (30mg/kg) for 5 days. |
Dosage form | 30mg/kg; i.p.; five times |
Applications | SGC707 inhibited the occurrence of endometriosis, promoted deciduoma formation, and improved embryonic development. |
References: | |
| Cas No. | 1687736-54-4 | SDF | |
| Chemical Name | 1-(isoquinolin-6-yl)-3-(2-oxo-2-(pyrrolidin-1-yl)ethyl)urea | ||
| Canonical SMILES | O=C(NCC(N1CCCC1)=O)NC2=CC3=CC=NC=C3C=C2 | ||
| Formula | C16H18N4O2 | M.Wt | 298.34 |
| Solubility | ≥ 29.8mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3519 mL | 16.7594 mL | 33.5188 mL |
| 5 mM | 670.4 μL | 3.3519 mL | 6.7038 mL |
| 10 mM | 335.2 μL | 1.6759 mL | 3.3519 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)